A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypertriglyceridemia
Latest Information Update: 12 Feb 2026
At a glance
- Drugs SHR-1918 (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 09 Feb 2026 Planned initiation date changed from 1 Jan 2026 to 1 Feb 2026.
- 28 Jan 2026 New trial record